-
Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key Australian oncology meeting
-
Both Noxopharm and independent investigators have abstracts accepted
-
DARRT-1 interim data showing high incidence of a durable anti-cancer effect at 6 months
-
Retrospective review by investigators showing Veyonda® significantly increasing the anti-cancer response to experimental radionuclide, 177lutetium-PSMA-617
For further information please download the attached PDF:
Download this document
